What's new? Log in Free sign up

Mirum Pharmaceuticals (MIRM)

Company Profile

Company profile

Ticker

MIRM

Exchange

Website

www.mirumpharma.com

CEO

Mr. Christopher Peetz

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Olivia Ventures, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Mirum Pharmaceuticals AG, a company • Mirum Pharmaceuticals International B.V., a company ...

IRS number

831281555

MIRM stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

14 Apr 25

Registration of securities for employees

26 Feb 25

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Quarterly report

12 Nov 24

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Quarterly report

7 Aug 24

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Christopher Peetz

Patrick J Heron

Notice of proposed sale of securities

Notice of proposed sale of securities

Patrick J Heron

Patrick J Heron

Patrick J Heron

Financial summary

Financial statements Chart MIRM financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	222.93 mm	222.93 mm	222.93 mm	222.93 mm	222.93 mm	222.93 mm
Cash burn (monthly)	155.33 k	880.58 k	8.12 mm	7.41 mm	1.69 mm	(no burn)
Cash used (since last report)	563.73 k	3.20 mm	29.48 mm	26.90 mm	6.13 mm	n/a
Cash remaining	222.36 mm	219.73 mm	193.45 mm	196.03 mm	216.80 mm	n/a
Runway (months of cash)	1431.5	249.5	23.8	26.4	128.3	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

MIRM institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	206	183	+12.6%
Opened positions	41	35	+17.1%
Closed positions	18	18	–
Increased positions	74	74	–
Reduced positions	59	44	+34.1%

13F shares	Current	Prev Q	Change
Total value	2.05 tn	1.95 tn	+5.1%
Total shares	63.42 mm	63.50 mm	-0.1%
Total puts	99.70 k	167.30 k	-40.4%
Total calls	2.60 k	177.20 k	-98.5%
Total put/call ratio	38.3	0.9	+3961.5%

Largest owners	Shares	Value	Change
Frazier Life Sciences Management	6.57 mm	$271.69 bn	0.0%
JHG Janus Henderson	4.58 mm	$189.48 bn	+2.3%
Frazier Life Sciences IX	3.57 mm	$94.27 mm	0.0%
BlackRock	3.43 mm	$142.02 bn	+2.0%
Biotechnology Value Fund L P	3.08 mm	$120.51 mm	0.0%
BVF	2.80 mm	$115.64 bn	-9.1%
Eventide Asset Managment	2.61 mm	$107.80 bn	-24.3%
Vanguard	2.42 mm	$100.26 bn	-2.9%
New Enterprise Associates 16	2.19 mm	$65.78 mm	0.0%
RiverVest Venture Fund IV	1.62 mm	$32.28 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Eventide Asset Managment	2.61 mm	-838.43 k	-24.3%
Cadian Capital Management	0.00	-475.71 k	EXIT
STT State Street	1.38 mm	-412.10 k	-23.0%
JPM JPMorgan Chase & Co.	385.14 k	+357.38 k	+1287.3%
BVF	2.80 mm	-279.39 k	-9.1%
BNP Paribas Arbitrage	261.64 k	+261.64 k	NEW
RJF Raymond James Financial	256.61 k	+256.61 k	NEW
Nuveen Asset Management	722.16 k	+229.75 k	+46.7%
D. E. Shaw & Co.	157.35 k	+157.35 k	NEW
Marshall Wace	175.91 k	+152.19 k	+641.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MIRM insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Mar 25	Jolanda Howe	Common Stock	Sell	Dispose S	No	Yes	44.4484	2,415	107.34 k	2,426
17 Mar 25	Radovich Peter	Common Stock	Sell	Dispose S	No	No	44.2143	7,879	348.36 k	18,672
17 Mar 25	Christopher Peetz	Common Stock	Sell	Dispose S	No	No	44.2143	27,279	1.21 mm	138,641
17 Mar 25	Jolanda Howe	Common Stock	Sell	Dispose S	No	Yes	44.3592	1,806	80.11 k	4,841
17 Mar 25	Jolanda Howe	Common Stock	Sell	Dispose S	No	Yes	44.7481	2,789	124.80 k	6,647
17 Mar 25	Jolanda Howe	Common Stock	Sell	Dispose S	No	Yes	44.3341	50,111	2.22 mm	9,436
17 Mar 25	Jolanda Howe	Common Stock	Option exercise	Acquire M	No	No	2.94	52,900	155.53 k	59,547
17 Mar 25	Jolanda Howe	Common Stock	Sell	Dispose S	No	No	44.2143	2,900	128.22 k	6,647
17 Mar 25	Jolanda Howe	Stock Option Common Stock	Option exercise	Dispose M	No	No	2.94	52,900	155.53 k	0
17 Mar 25	Patrick J Heron	Common Stock	Buy	Acquire P	Yes	No	43.9338	21	922.61	168,672

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

FDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and

HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $72

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $66 to $72.

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $50 to $55.

Mirum Pharmaceuticals Q4 2024 GAAP EPS $(0.49) Misses $(0.28) Estimate, Sales $99.430M Beat $96.606M Estimate

Mirum Pharmaceuticals Q4 Sales $99.430M Beat $96.606M Estimate

Press releases

From Benzinga Pro

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase

LIVMARLI Now Approved in Japan for ALGS and PFIC

- LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.